Korea Institute of Intellectual Property, KIPS Center, 9th FL. 647-9, Yeoksam-dong, Gangnam-gu, Seoul, 135-980, Korea,
Adv Biochem Eng Biotechnol. 2013;131:153-69. doi: 10.1007/10_2012_136.
RNA aptamers, small oligonucleotides derived by an in-vitro selection process called SELEX (Systematic Evolution of Ligands by EXperimental enrichment), are important candidates for therapeutic and diagnostic applications. RNA aptamers have high affinity and specificity for their target molecules. In this review, we describe methods for generating RNA aptamers (the SELEX technique and modified SELEX processes) and therapeutic applications for diseases such as neovascular age-related macular degeneration (AMD), inflammatory diseases, and obesity. We also analyze the social networks among researchers and organizations (universities, research institutes, firms, etc.) that are active in the pursuit of aptamer-based therapeutic approaches. This study provides relevant information on recent research trends in RNA aptamers.
RNA 适体是通过一种称为 SELEX（体外配体系统进化）的筛选过程从小分子核苷酸中衍生出来的，是治疗和诊断应用的重要候选物。RNA 适体对其靶分子具有高亲和力和特异性。在这篇综述中，我们描述了生成 RNA 适体的方法（SELEX 技术和改良的 SELEX 过程）以及在治疗新生血管性年龄相关性黄斑变性（AMD）、炎症性疾病和肥胖症等疾病方面的应用。我们还分析了在基于适体的治疗方法研究中活跃的研究人员和组织（大学、研究所、公司等）之间的社会网络。本研究提供了有关 RNA 适体的最新研究趋势的相关信息。
